Avidity Biosciences IncNASDAQ:RNA
- LAST PRICE23.5500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots23.5500/ 1
- Ask / Lots23.6900/ 4
- Open / Previous Close23.5500 / 23.5500
- Day Range
- 52 Week Range
- Volume57,663
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RNA |
|---|---|---|
| 09:32 ET | 26503 | 23.96 |
| 09:34 ET | 24175 | 23.815 |
| 09:36 ET | 2200 | 23.65 |
| 09:38 ET | 100 | 23.71 |
| 09:39 ET | 2140 | 23.55 |
Apr 11, 2024
DJ Avidity Biosciences Price Target Maintained With a $35.00/Share by Needham, from 7:34AM ET on Thursday Apr 11, 2024 by Dow Jones
7:34AM ET on Thursday Apr 11, 2024 by Dow Jones
Mar 27, 2024
Avidity Biosciences to Participate in Upcoming Investor Conferences, from 9:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
9:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
Mar 21, 2024
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Thursday Mar 21, 2024 by Dow Jones
4:05PM ET on Thursday Mar 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Avidity Biosciences Inc | 2.2B | -8.1x | --- |
Vera Therapeutics Inc | 2.2B | -17.3x | --- |
Geron Corp | 2.2B | -11.4x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -8.0x | --- |
Dyne Therapeutics Inc | 2.1B | -6.3x | --- |
Keros Therapeutics Inc | 2.1B | -11.4x | --- |
Company Information
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Contact Information
- Headquarters
- 10578 SCIENCE CENTER DRIVE, SUITE 125SAN DIEGO, CA, United States 92121
- Phone
- 858-401-7900
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Troy Wilson
- President, Chief Executive Officer, Director
- Sarah Boyce
- Chief Financial and Chief Business Officer
- Michael Maclean
- Chief Human Resource Officer
- Teresa Mccarthy
- Chief Scientific and Technical Officer
- W. Michael Flanagan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $9.6M |
Shares Outstanding | 94.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-2.90 |
Book Value | $6.32 |
P/E Ratio | -8.1x |
Price/Sales (TTM) | 233.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,464.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
